A history of cancer chemotherapy.
By V. Devita, E. Chu. Cancer Research, 2008
1,625 citations recorded by the source corpus.
Subfields: Genetics, Hematology, Oncology
View Paper: https://www.semanticscholar.org/paper/120129f3ac1f276016aa9490c0636c433f538061
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Genetics
In Hematology
In Oncology
Citations in the corpus
- Current state of melanoma diagnosis and treatment (2019, background): “In the 1940s two pharmacologists from Yale, Alfred Gilman and Louis Goodman, were asked by the US Office of Scientific Research and Development, to explore therapeutic uses for these chemicals.(12,97) Gilman and Goodman found that one mustard compound, nitrogen mustard, effectively treated mice with”
- Antibody-drug conjugates: recent advances in conjugation and linker chemistries (2016, background): “Over the past half century, cancer management has improved significantly along with the advancement of chemotherapy (DeVita and Chu, 2008).”
- Assessment of the Evolution of Cancer Treatment Therapies (2011, background): “Since 1990, the incidence and mortality of cancer have been declining and despite the increase in the elderly population [22], mortality rates for the United States declined from 2005 to 2007.”
- Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics (2022, background): “In the following years, the idea of combination therapy was introduced for acute lymphocytic leukemia and non-Hodgkin’s lymphoma patients that were also supplemented with supportive medical care to enhance the quality of life.(21) In the second half of the twentieth century, a series of reports have”
- Site-specific antibody drug conjugates for cancer therapy (2013, background): “These chemotherapy drugs included the folate and purine analogs (methotrexate, 6-mercaptopurine), microtubule polymerization inhibitors/promoters (vinca alkaloids, taxanes) and DNA damaging agents (anthracyclines, nitrogen mustard).(7) These compounds target cancer cells but also other dividing cell”
- Smart nanocarrier-based drug delivery systems for cancer therapy and toxicity studies: A review (2018, background): “Chemotherapy [3,4] plays a vital role in treating undetectable cancer micro-focuses and free cancer cells.”
- Nanoparticles in the clinic: An update (2019, background): “As the first clinically approved nanoparticle to deliver a synergistic combination of free drugs, VYXEOS can pave the way for new combination nanoparticle formulations that leverage widely-utilized combination chemotherapy regimens from the clinic.(8,9) Patisiran/ONPATTRO is an siRNA-delivering lipi”